ATE138575T1 - METHOD FOR INACTIVATION OF VIRUSES IN PHARMACEUTICAL COMPOSITIONS CONTAMINATED WITH VIRUSES - Google Patents

METHOD FOR INACTIVATION OF VIRUSES IN PHARMACEUTICAL COMPOSITIONS CONTAMINATED WITH VIRUSES

Info

Publication number
ATE138575T1
ATE138575T1 AT90909877T AT90909877T ATE138575T1 AT E138575 T1 ATE138575 T1 AT E138575T1 AT 90909877 T AT90909877 T AT 90909877T AT 90909877 T AT90909877 T AT 90909877T AT E138575 T1 ATE138575 T1 AT E138575T1
Authority
AT
Austria
Prior art keywords
viruses
plasma
blood product
inactivation
pharmaceutical compositions
Prior art date
Application number
AT90909877T
Other languages
German (de)
Inventor
Michael E Hrinda
Alisa Rose D
George Crissman Tarr
Original Assignee
Rorer Int Overseas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rorer Int Overseas filed Critical Rorer Int Overseas
Application granted granted Critical
Publication of ATE138575T1 publication Critical patent/ATE138575T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention provides a fail-safe combination of chemical and physical means for rendering a blood product which comprises a labile blood protein free of viruses without incurring protein denaturation. The blood product is contacted with an effective amount of a selected chemical disinfectant, preferably, sodium thiocyanate in combination with a physical process, preferably, ultrafiltration. The blood product may be plasma, serum, plasma concentrate, cryoprecipitate, cryosupernatant, plasma fractionation precipitate or plasma fractionation supernatant containing viruses such as hepatitis or human immunodeficiency virus.
AT90909877T 1989-06-15 1990-06-13 METHOD FOR INACTIVATION OF VIRUSES IN PHARMACEUTICAL COMPOSITIONS CONTAMINATED WITH VIRUSES ATE138575T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36685589A 1989-06-15 1989-06-15

Publications (1)

Publication Number Publication Date
ATE138575T1 true ATE138575T1 (en) 1996-06-15

Family

ID=23444851

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90909877T ATE138575T1 (en) 1989-06-15 1990-06-13 METHOD FOR INACTIVATION OF VIRUSES IN PHARMACEUTICAL COMPOSITIONS CONTAMINATED WITH VIRUSES

Country Status (9)

Country Link
US (1) US5300433A (en)
EP (1) EP0431129B1 (en)
JP (1) JP3297433B2 (en)
AT (1) ATE138575T1 (en)
CA (1) CA2034489C (en)
DE (1) DE69027187T2 (en)
DK (1) DK0431129T3 (en)
ES (1) ES2087156T3 (en)
WO (1) WO1990015613A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT402891B (en) * 1991-06-20 1997-09-25 Immuno Ag METHOD FOR PRODUCING AN INACTIVATED BLOOD PRODUCT
AT408191B (en) * 1991-08-19 2001-09-25 Haemosan Erzeugung Pharmazeuti METHOD FOR INACTIVATING PRIONS
US5792835A (en) * 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
AT399818B (en) * 1992-04-24 1995-07-25 Immuno Ag METHOD FOR PRODUCING A HIGH PURIFIED VIRUS-SAFE FACTOR VIII PREPARATION
WO1994013329A1 (en) * 1992-12-16 1994-06-23 Immuno Aktiengesellschaft Process for preparing a virus-safe biological composition
DE4320294A1 (en) * 1993-06-18 1994-12-22 Immuno Ag Use of human protein C to prevent and treat platelet deposits
HRP940645A2 (en) * 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
DE4434538C2 (en) * 1993-10-06 2000-08-10 Immuno Ag Virus inactivation method in the presence of a polyether and a chaotropic agent
DE4435485C1 (en) * 1994-10-04 1996-03-21 Immuno Ag Process for obtaining high-purity von Willebrand factor
WO1996032130A1 (en) * 1995-04-10 1996-10-17 Baxter International Inc. The use of cross-linked hemoglobin in treating subarachnoid hemorrhage
US5741894A (en) * 1995-09-22 1998-04-21 Baxter International, Inc. Preparation of pharmaceutical grade hemoglobins by heat treatment in partially oxygenated form
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
US7026468B2 (en) * 1996-07-19 2006-04-11 Valentis, Inc. Process and equipment for plasmid purification
US7807822B2 (en) * 1996-08-01 2010-10-05 Robert Bridenbaugh Methods for purifying nucleic acids
UA64742C2 (en) * 1997-12-24 2004-03-15 Альфа Терапевтик Корпорейшн Process for producing intravenously-administrable gamma globulin solution and product manufactured by this process
US6270723B1 (en) * 1998-06-15 2001-08-07 Bbi Bioseq, Inc. Rapid cryobaric sterilization and vaccine preparation
US6441144B1 (en) 1999-05-20 2002-08-27 Alpha Therapeutic Corporation Method for repairing dual virally inactivated immune globulin for intravenous administration
US6747132B2 (en) 2000-11-29 2004-06-08 Apex Biosciences, Inc. Methods for the synthesis of a modified hemoglobin solution
US7038016B2 (en) * 2001-08-21 2006-05-02 Apex Bioscience, Inc. Methods for purification of an activated PEG solution and for the synthesis of a modified hemoglobin solution
ATE421328T1 (en) * 2002-02-22 2009-02-15 Intracel Recources Llc STERILE IMMUNOGENE NON-TUMORIGEN TUMOR CELL COMPOSITIONS AND METHODS
CA2498518A1 (en) * 2002-09-13 2004-03-25 Valentis, Inc. Apparatus and method for preparative scale purification of nucleic acids
CA2560613C (en) * 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
WO2006023774A2 (en) * 2004-08-20 2006-03-02 Imquest Biosciences, Inc. Plasma or serum fraction for treatment and prevention of viral infections and related conditions
KR101555058B1 (en) * 2005-07-29 2015-09-22 애보트 래버러토리즈 게엠베하 Process for producing sterilized pancreatin powder
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
EP2550362B1 (en) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
WO2012069474A2 (en) * 2010-11-24 2012-05-31 H. Lundbeck A/S A method for reducing potential virus burden in a sample by cyanate treatment
CA2821711C (en) 2010-12-15 2017-10-10 Baxter International Inc. Eluate collection using conductivity gradient
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP2568289A3 (en) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (en) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 env glycoprotein variant
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (en) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2475572A1 (en) * 1980-02-11 1981-08-14 Pasteur Institut PROCESS FOR OBTAINING LIPID ENVELOPE VIRUS FRAGMENTS, PARTICULARLY ANTIGENS USED AS VACCINES, PRODUCTS OBTAINED AND APPLICATIONS
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
JPS61500226A (en) * 1983-10-28 1986-02-06 ニュ−・イングランド・メディカル・センタ−・ホスピタルズ・インコ−ポレ−テッド Purification and isolation of blood clotting proteins using conformation-specific antibodies
US4673733A (en) * 1985-04-11 1987-06-16 Sudhish Chandra Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents
AT385203B (en) * 1985-04-26 1988-03-10 Immuno Ag METHOD FOR PRODUCING AN EARLY SUMMER MENINGOCEPHALITIS VIRUS (TBE VIRUS) VACCINE
US4732683A (en) * 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
DD264137A1 (en) * 1987-09-22 1989-01-25 Univ Leipzig AGENTS FOR CONTROLLING VIRUSES IN CULTURAL PLANTS

Also Published As

Publication number Publication date
JPH04501429A (en) 1992-03-12
DK0431129T3 (en) 1996-06-17
CA2034489A1 (en) 1990-12-16
WO1990015613A1 (en) 1990-12-27
EP0431129A1 (en) 1991-06-12
EP0431129A4 (en) 1992-03-11
EP0431129B1 (en) 1996-05-29
CA2034489C (en) 1996-07-16
DE69027187D1 (en) 1996-07-04
ES2087156T3 (en) 1996-07-16
US5300433A (en) 1994-04-05
DE69027187T2 (en) 1996-10-31
JP3297433B2 (en) 2002-07-02

Similar Documents

Publication Publication Date Title
ATE138575T1 (en) METHOD FOR INACTIVATION OF VIRUSES IN PHARMACEUTICAL COMPOSITIONS CONTAMINATED WITH VIRUSES
ATE54828T1 (en) TREATMENT OF BIOLOGICAL AND PHARMACEUTICAL PRODUCTS ADOPTED ON A SOLID PHASE WITH VIRAL AND PYROGENIC INACTIVATING AGENTS.
JPS6051116A (en) Composition containing lipid-containing virus-free protein and manufacture
ATE231549T1 (en) METHOD FOR PRESERVING INFECTIOUS RECOMBINING VIRUSES, VIRAL AQUEOUS SUSPENSION AND MEDICAL USE THEREOF
ATE194921T1 (en) METHOD FOR INACTIVATION OF VIRUSES
DE69535758D1 (en) LIPID ANALOGUE FOR THE TREATMENT OF VIRAL INFECTIONS
ATE36457T1 (en) METHOD OF INACTIVATING REPRODUCTIVE pathogens.
Burnouf et al. Viral safety of human platelet lysate for cell therapy and regenerative medicine: moving forward, yes, but without forgetting the past
ATE286407T1 (en) METHOD FOR INACTIVATION OF PATHOGENS USING BROAD SPECTRUM PULSE LIGHT
KR950010898A (en) Sterilization of Recombinant Human Serum Albumin Pharmaceutical Formulations
DE3686108D1 (en) USE OF P-CHLOROPHENOXYACETATE OF N, N-DIMETHYL BIGUANIDE FOR THE TREATMENT OF NEUROPATHIA AND NERVE DEGENERATION.
ATE189394T1 (en) METHOD OF TREATING VIRAL INFECTIONS
DE3584775D1 (en) COMPOSITION FOR TREATING DISEASES Suffering from HAEMOPHILIA-A-INHIBITOR.
ATE44877T1 (en) PROCESS FOR PASTEURIZATION OF HUMAN PLASMA.
ATA145786A (en) METHOD FOR INACTIVATING VARIABLE FILTERABLE DISEASES
ATE42899T1 (en) PROCESSES FOR PASTEURIZATION OF PLASMA OR CONCENTRATES OF COAGAGING FACTORS II, VII, IX, AND X.
FI953756A0 (en) Procedure for inactivating lipid envelope-free viruses
DE69733664D1 (en) Method of inactivating viruses and lyophilizing blood proteins
ATE194648T1 (en) METHOD FOR INACTIVATION OF VIRUSES IN PROTEIN PREPARATIONS
DE3750886D1 (en) Use of an immunoglobulin-containing preparation for the prophylaxis and therapy of AIDS in humans.
DK82892D0 (en) APPLICATION OF BRAIN ADDITION FROM BEES AND WHEPS FOR THE PREPARATION OF MEDICINAL PRODUCTS TO TREAT INFECTIONS
DE69014501D1 (en) Process for the treatment of titanium alloy and piece made therewith.
DE3777022D1 (en) METHOD AND PREPARATION FOR INACTIVATING VIRUSES.
ATE196424T1 (en) METHOD AND COMPOSITION FOR TREATING HERPES-LIKE DISEASES
EP0330647A3 (en) The use of chymotrypsin for the inactivation of prekallikrein activator

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time